Format

Send to

Choose Destination
J Comp Eff Res. 2018 Dec;7(12):1195-1207. doi: 10.2217/cer-2018-0057. Epub 2018 Oct 23.

Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA.

Author information

1
Navigant Consulting, Inc., 101 California Street, Suite 4100, San Francisco, CA 94111, USA.
2
Retinal Consultants of Arizona, 1101 E Missouri Ave, Phoenix, AZ 85014, USA.
3
USC Roski Eye Institute, Keck School of Medicine, University of Southern California, 1450 San Pablo St Fourth Floor, Los Angeles, CA 90033, USA.
4
Department of Ophthalmology, Wills Eye Hospital, Sidney Kimmel Medical College, Thomas Jefferson University, 840 Walnut Street, Suite 1510, Philadelphia, PA 19107, USA.
5
Cleveland Clinic Cole Eye Institute, 9500 Euclid Ave, Cleveland, OH 44195, USA.
6
Icahn School of Medicine at Mount Sinai, Department of Environmental Medicine & Public Health, 1 Gustave L Levy Place, New York, NY 10029, USA.

Abstract

BACKGROUND:

Vitreomacular traction (VMT) treatment options include watchful waiting, vitrectomy and intravitreal ocriplasmin injection (Jetrea®). This analysis used results from the recently completed OASIS randomized clinical trial to evaluate the 2-year budget impact of ocriplasmin injection availability for treatment of Stage I or II VMT without epiretinal membrane formation in a modeled US health plan.

MATERIALS & METHODS:

 VMT prevalence, treatment patterns and disease resolution rates were from literature, a US retinal-specialist survey and the OASIS trial. Medicare payment rates were applied and a national scenario analysis was conducted.

RESULTS:

With ocriplasmin available, vitrectomy use and complications-related costs decreased. Budget impact of ocriplasmin to the health plan was US$143,599 over 2 years or US$0.0060 per-member per-month.

CONCLUSION:

Ocriplasmin was projected to be minimally cost-additive at US$0.0060 per-member per-month over 2 years.

KEYWORDS:

pharmacolysis; vitreoretinal adhesion; vitreoretinal traction

PMID:
30350717
DOI:
10.2217/cer-2018-0057
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center